<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-386X</journal-id>
<journal-title><![CDATA[Revista Facultad Nacional de Salud Pública]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Fac. Nac. Salud Pública]]></abbrev-journal-title>
<issn>0120-386X</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Antioquia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-386X2017000100016</article-id>
<article-id pub-id-type="doi">10.17533/udea.rfnsp.v35n1a03</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Aportes al debate de legalización del uso medicinal de la marihuana en Colombia]]></article-title>
<article-title xml:lang="en"><![CDATA[Contributions to the debate on the legalization of marijuana as medicine in Colombia]]></article-title>
<article-title xml:lang="pt"><![CDATA[Contributos ao debate sobre a legalização da maconha para uso medicinal na Colômbia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castaño-Pérez]]></surname>
<given-names><![CDATA[Guillermo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Velásquez]]></surname>
<given-names><![CDATA[Elvia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Olaya-Peláez]]></surname>
<given-names><![CDATA[Álvaro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Católica Luis Amigó  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Asociación Colombiana de Adiccionología  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Antioquia  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>01</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>01</month>
<year>2017</year>
</pub-date>
<volume>35</volume>
<numero>1</numero>
<fpage>16</fpage>
<lpage>26</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-386X2017000100016&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-386X2017000100016&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-386X2017000100016&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Es intenso el debate sobre legalización de la marihuana para usos terapéuticos, que busca minimizar la criminalización del usuario. Paradójicamente, a pesar de la evidencia de efectos nocivos de la marihuana su consumo aumenta, hay altas prevalencias de vida y surgen variedades más potentes y peligrosas de cannabis.  Objetivo: Analizar la información disponible sobre marihuana, describiendo la evidencia que existe y, de esta manera, aportar al debate actual sobre la legalización de esta sustancia para usos medicinales en Colombia.  Metodología: Revisión sobre componentes de la marihuana, efectos y evidencia terapéutica.  Resultados:  La planta contiene más de 400 compuestos activos y de la mayoría se desconoce su toxicidad. Contiene, además, unos 66 cannabinoides. Hay alguna evidencia del efecto medicinal de algunos compuestos, pero, falta investigación. Una cosa son cannabinoides sintéticos y derivados de la planta, otra el consumo de la &#8220;yerba&#8221;.  Discusión:  Componentes benéficos de la planta no pueden, hasta hoy, separarse de los tóxicos. En uso terapéutico o recreativo se ingieren unos y otros. Cannabinoides producen en humanos un síndrome que altera funciones cerebrales como memoria, estado de ánimo, sueño, atención, humor, coordinación, cognición, percepción del tiempo y distorsión de la información, entre otras alteraciones, además de generar dependencia, tolerancia, adicción y síndrome de abstinencia, todas ya probadas.  Conclusiones:  el desconocimiento de efectos adversos del uso de la planta de marihuana como medicamento, sin conocer muy bien qué se está consumiendo, plantea importantes riesgos para la salud.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Currently there is an intense debate regarding the legalization of marijuana for therapeutic uses seeking to decrease consumer criminalization. Paradoxically, despite the evidence of hazardous effects of marijuana with high prevalence of life, and new varieties of more powerful and more dangerous cannabis.  Objective:  To analyze the available information on marijuana describing the evidence that exists and, in this way, contribute to the current debate on the legalization of this substance for medicinal uses in Colombia  Methodology:  This study is a bibliographical review based on the components of marijuana, adverse effects and evidence of therapeutic effects. Results: The marijuana plant contains more than 400 active components, the toxicity of the majority of these components is unknown, and it also contains approximately 66 cannabinoids. There is scientific evidence of the medicinal effect of some components, yet there is still not enough research. One thing is synthetic cannabinoids from pharmaceutical research and derived from the marijuana plant, and another thing is the use of the plant as &#8220;weed&#8221;. Discussion: Technically up-to-date, the beneficial components of the marijuana plant cannot be separated from the toxic ones, so when it is used for therapeutic or recreational purposes people ingest both. Cannabinoids produce in human beings a syndrome which alters important brain functions like memory, mood, sleep, attention, humor, coordination, cognition, time perception, and distortion of information, among others. This also includes dependence, tolerance, addiction and withdrawal syndromes already proven. Conclusions: A lack of knowledge of the adverse effects of the use of the marijuana plant as such poses a serious health risk when used as medication without knowing exactly what a person is using.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo Atualmente, existe um debate intenso sobre a legalização da maconha para usos terapêuticos, visando minimizar a criminalização do consumidor. Paradoxalmente, apresar da evidência dos efeitos negativos, o consumo e a prevalência da maconha aumentam. Também surgem novas de variedades de cânabis, mais potentes e perigosas.  Objetivo :  analisar a informação disponível sobre a maconha descrevendo a evidência de que existe e, assim, contribuir para o actual debate sobre a legalização da substância para uso médico na Colômbia  Metodologia:  Revisão bibliográfica sobre os componentes na maconha, efeitos adversos e evidência de efeitos terapêuticos.  Resultados:  A planta de maconha tem mais de 400 compostos ativos e a toxicidade da maioria deles é desconhecida. Além disso, contém 66 canabinóides. Existe alguma evidencia científica sobre o efeito medicinal dalguns compostos, mais ainda é preciso pesquisar mais. O consumo da &#8220;erva&#8221; diferencia-se dos canabinóides sintéticos e dos derivados da planta da maconha produzidos através de pesquisa farmacêutica.  Discussão:  Neste momento, os componentes benéficos da maconha não podem ser separados tecnicamente dos tóxicos. Por isso, consumi-la para usos terapêuticos ou recreativo implica ingerir tanto uma coisa quanto a outra. Nos humanos, os canabinóides produzem uma síndrome que desvirtua a informação e altera funções cerebrais importantes: a memória, o temperamento, o sonho, a atenção, o humor, a coordenação, a cognição, a percepção do tempo, entre outras. Além da dependência, já se comprovaram a tolerância, a adição e a síndrome de abstinência.  Conclusões:  poderiam surgir importantes riscos para a saúde derivados do uso da maconha como medicamento, desconhecendo seus efeitos adversos. Não há claridade sobre o que se consume.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[hábito de fumar marihuana]]></kwd>
<kwd lng="es"><![CDATA[abuso de marihuana]]></kwd>
<kwd lng="es"><![CDATA[marihuana medicinal]]></kwd>
<kwd lng="es"><![CDATA[riesgo.]]></kwd>
<kwd lng="en"><![CDATA[marijuana]]></kwd>
<kwd lng="en"><![CDATA[therapeutic uses]]></kwd>
<kwd lng="en"><![CDATA[cannabis]]></kwd>
<kwd lng="en"><![CDATA[legalization debate]]></kwd>
<kwd lng="en"><![CDATA[health risks]]></kwd>
<kwd lng="pt"><![CDATA[hábito de fgumar maconha]]></kwd>
<kwd lng="pt"><![CDATA[abuso de maconha]]></kwd>
<kwd lng="pt"><![CDATA[maconha medicinal]]></kwd>
<kwd lng="pt"><![CDATA[risco]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<collab>Gobierno Nacional de la República de Colombia, Observatorio de Drogas. Ministerio de Justicia</collab>
<source><![CDATA[Estudio Nacional de Consumo de Sustancias Psicoactivas en Población Escolar Colombia]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Observatorio de Drogas de Colombia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="book">
<collab>Comunidad Andina, Programa Antidrogas Ilícitas en la Comunidad Andina, Unión Europea</collab>
<source><![CDATA[II Estudio Epidemiológico Andino sobre Consumo de Drogas en la Población Universitaria Informe. 2012]]></source>
<year>2012</year>
<publisher-loc><![CDATA[Lima ]]></publisher-loc>
<publisher-name><![CDATA[Corporación UE-CAN]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="book">
<collab>República de Colombia. Ministerio de la Protección Social, Dirección Nacional de Estupefacientes</collab>
<source><![CDATA[Estudio Nacional de Consumo de Sustancias Psicoactivas en Colombia]]></source>
<year>2008</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de la Protección Social, Dirección Nacional de Estupefacientes]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Chemical constituents of marijuana: the complex mixture of natural cannabinoids]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elsohly]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Slade]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Life Sci.]]></source>
<year>2005</year>
<volume>78</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>539-48</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Pharmacology and effects of cannabis: a brief review]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ashton]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
</person-group>
<source><![CDATA[Br J Psychiatry J Ment Sci]]></source>
<year>2001</year>
<volume>178</volume>
<page-range>101-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Neuroprotective antioxidants from marijuana]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hampson]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Grimaldi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lolic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wink]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenthal]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Axelrod]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann N Y Acad Sci]]></source>
<year>2000</year>
<volume>899</volume>
<page-range>274-82</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fabre]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cannabis, chanvre et haschich : l'éternel retour]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Paris ]]></publisher-loc>
<publisher-name><![CDATA[Editions l&#8217;Harmattan]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pertwee]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Howlett]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Abood]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[SPH]]></given-names>
</name>
<name>
<surname><![CDATA[Di Marzo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Elphick]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacol Rev.]]></source>
<year>2010</year>
<volume>62</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>588-631</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The endogenous opioid system: a common substrate in drug addiction]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trigo]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Martin-García]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Berrendero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Robledo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Maldonado]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug Alcohol Depend]]></source>
<year>2010</year>
<volume>108</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>183-94</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sugiura]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kondo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sukagawa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nakane]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shinoda]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Itoh]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Biochem Biophys Res Commun]]></source>
<year>1995</year>
<volume>215</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>89-97</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Plant, synthetic, and endogenous cannabinoids in medicine]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Di Marzo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Petrocellis]]></surname>
<given-names><![CDATA[LD.]]></given-names>
</name>
</person-group>
<source><![CDATA[Annu Rev Med]]></source>
<year>2006</year>
<volume>57</volume>
<page-range>553-74</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Clinical Pharmacodynamics of Cannabinoids]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grotenhermen]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Cannabis Ther]]></source>
<year>2004</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>29-78</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[New resorcinol-anandamide &#8220;hybrids&#8221; as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brizzi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Brizzi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Cascio]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Corelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Guida]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ligresti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[J Med Chem]]></source>
<year>2009</year>
<volume>52</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2506-14</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caffarel]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno-Bueno]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cerutti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Palacios]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Guzman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mechta-Grigoriou]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Oncogene]]></source>
<year>2008</year>
<volume>27</volume>
<numero>37</numero>
<issue>37</issue>
<page-range>5033-44</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Black]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rogacki]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Featherstone]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Senyah]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Giardino]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Psychopharmacology (Berl).]]></source>
<year>2011</year>
<volume>215</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>149-63</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cannabinoids in health and disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kogan]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Mechoulam]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Dialogues Clin Neurosci]]></source>
<year>2007</year>
<volume>9</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>413-30</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="">
<collab>National Institute on Drug Abuse</collab>
<source><![CDATA[¿La marihuana es un medicamento?]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Svízenská]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Dubový]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sulcová]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacol Biochem Behav]]></source>
<year>2008</year>
<volume>90</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>501-11.</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Adverse effects of medical cannabinoids: a systematic review]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Collet]]></surname>
<given-names><![CDATA[J-P]]></given-names>
</name>
<name>
<surname><![CDATA[Shapiro]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ware]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[Can Med Assoc J.]]></source>
<year>2008</year>
<volume>178</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1669-78</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Therapeutic potential of cannabinoids in CNS disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Croxford]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<source><![CDATA[CNS Drugs]]></source>
<year>2003</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>179-202</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Neurobiology of marijuana abuse]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abood]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
</person-group>
<source><![CDATA[Trends Pharmacol Sci]]></source>
<year>1992</year>
<volume>13</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>201-6</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cannabinoid addiction: behavioral models and neural correlates]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maldonado]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez de Fonseca]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Neurosci Off J Soc Neurosci]]></source>
<year>2002</year>
<volume>22</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>3326-31</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hutcheson]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Tzavara]]></surname>
<given-names><![CDATA[ET]]></given-names>
</name>
<name>
<surname><![CDATA[Smadja]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Valjent]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Roques]]></surname>
<given-names><![CDATA[BP]]></given-names>
</name>
<name>
<surname><![CDATA[Hanoune]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Br J Pharmacol]]></source>
<year>1998</year>
<volume>125</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1567-77</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Time course for the induction and maintenance of tolerance to Delta (9)-tetrahydrocannabinol in mice]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bass]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug Alcohol Depend.]]></source>
<year>2000</year>
<volume>60</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>113-9</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Di Marzo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Berrendero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bisogno]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cavaliere]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[J Neurochem]]></source>
<year>2000</year>
<volume>74</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1627-35</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Changes in the Cannabinoid Receptor Binding, G Protein Coupling, and Cyclic AMP Cascade in the CNS of Rats Tolerant to and Dependent on the Synthetic Cannabinoid Compound CP55,940]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubino]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Viganò]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Massi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Parolaro]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[J Neurochem.]]></source>
<year>2002</year>
<volume>75</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>2080-6</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cannabinoid tolerance and dependence: a review of studies in laboratory animals]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cebeira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Ruiz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacol Biochem Behav]]></source>
<year>2005</year>
<volume>81</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>300-18</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cannabinoid-induced tolerance is associated with a CB1 receptor G protein coupling switch that is prevented by ultra-low dose rimonabant]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paquette]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[H-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Bakshi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Olmstead]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<source><![CDATA[Behav Pharmacol]]></source>
<year>2007</year>
<volume>18</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>767-76</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Complete adaptation to the memory disruptive effects of D9-tetrahydrocannabinol following 35 days of exposure]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deadwyler]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Heyser]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Hampson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurosci Res Commun]]></source>
<year>1995</year>
<volume>17</volume>
<page-range>9-18</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Identification of endocannabinoids and cannabinoid CB1 receptor mRNA in the pituitary gland.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonzalez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Manzanares]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Berrendero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Wenger]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Corchero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bisogno]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Neuroendocrinology]]></source>
<year>1999</year>
<volume>70</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>137-45</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Proporción de pacientes en South London con primer episodio de psicosis atribuible a Marihuana de alta potencia: Estudios de casos y controles]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Di Forti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Marconni]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carrá]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Trotta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bonomo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[The Lancet Psychiatry]]></source>
<year>2015</year>
<volume>2</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Chronic toxicology of cannabis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reece]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Toxicol Phila Pa]]></source>
<year>2009</year>
<volume>47</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>517-24</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anthony]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The epidemiology of cannabis dependence.]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Roffman]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Stephens]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<source><![CDATA[Cannabis Dependence: Its Nature, Consequences and Treatment]]></source>
<year>2006</year>
<page-range>58-105</page-range><publisher-loc><![CDATA[Cambridge, UK ]]></publisher-loc>
<publisher-name><![CDATA[Cambridge University Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bartke]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Maternal cannabinoid exposure and brain development: changes in the ontogeny of dopamine neurons. Marijuana/cannabinoids: neurobiology and neurophysiology.]]></source>
<year>1992</year>
<publisher-loc><![CDATA[Boca Raton, Fla ]]></publisher-loc>
<publisher-name><![CDATA[CRC Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brunton]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Lazo]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[KL.]]></given-names>
</name>
</person-group>
<source><![CDATA[Las Bases Farmacológicas de la Terapéutica]]></source>
<year>2006</year>
<edition>Undécima Edición</edition>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Mc Graw-Hill]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Gas chromatography/mass spectrometric and nuclear magnetic resonance spectrometric studies of carcinogenic polynuclear aromatic hydrocarbons in tobacco and marijuana smoke condensates.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Novotny]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bartle]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
</person-group>
<source><![CDATA[Anal Chem.]]></source>
<year>1976</year>
<volume>48</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>405-16</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Respiratory effects of non-tobacco cigarettes: a longitudinal study in general population.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sherrill]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Krzyzanowski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bloom]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Lebowitz]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Epidemiol]]></source>
<year>1991</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>132-7</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Cannabis: a health perspective and research agenda]]></source>
<year>1997</year>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Pharmacokinetics and pharmacodynamics of cannabinoids]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grotenhermen]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Pharmacokinet]]></source>
<year>2003</year>
<volume>42</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>327-60</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Control of pain initiation by endogenous cannabinoids]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calignano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[La Rana]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Giuffrida]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Piomelli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Nature.]]></source>
<year>1998</year>
<volume>394</volume>
<numero>6690</numero>
<issue>6690</issue>
<page-range>277-81</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rice]]></surname>
<given-names><![CDATA[ASC]]></given-names>
</name>
<name>
<surname><![CDATA[Farquhar-Smith]]></surname>
<given-names><![CDATA[WP]]></given-names>
</name>
<name>
<surname><![CDATA[Nagy]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<source><![CDATA[Prostaglandins Leukot Essent Fatty Acids]]></source>
<year>2002</year>
<volume>66</volume>
<numero>2-3</numero>
<issue>2-3</issue>
<page-range>243-56</page-range></nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cannabis: ¿medicina o droga?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ortiz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Psiquiatr Pública]]></source>
<year>1998</year>
<volume>10</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>68-72</page-range></nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Delta-9-THC in the treatment of spasticity associated with multiple sclerosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ungerleider]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Andyrsiak]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Fairbanks]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ellison]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Myers]]></surname>
<given-names><![CDATA[LW]]></given-names>
</name>
</person-group>
<source><![CDATA[Adv Alcohol Subst Abuse]]></source>
<year>1987</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>39-50</page-range></nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Henn]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Dittrich]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hofmann]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Arch Psychiatry Clin Neurosci]]></source>
<year>1990</year>
<volume>240</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cannabinoids reduce levodopa-induced dyskinesia in Parkinson&#8217;s disease: a pilot study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sieradzan]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dick]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Crossman]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Brotchie]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurology]]></source>
<year>2001</year>
<volume>57</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2108-11</page-range></nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Bronchodilator effect of delta1-tetrahydrocannabinol]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hartley]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Nogrady]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Seaton]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>1978</year>
<volume>5</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>523-5</page-range></nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cannabinoids in the treatment of glaucoma.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Järvinen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Pate]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Laine]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacol Ther]]></source>
<year>2002</year>
<volume>95</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>203-20</page-range></nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Future of Cannabis and Cannabinoids in Therapeutics]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Russo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[J Cannabis Ther]]></source>
<year>2004</year>
<volume>3</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>163-74</page-range></nlm-citation>
</ref>
<ref id="B49">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gordon]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Devinsky]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Epilepsia]]></source>
<year>2001</year>
<volume>42</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1266-72</page-range></nlm-citation>
</ref>
<ref id="B50">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Marijuana for intractable hiccups]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gilson]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Busalacchi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[The Lancet.]]></source>
<year>1998</year>
<volume>351</volume>
<numero>9098</numero>
<issue>9098</issue>
<page-range>267</page-range></nlm-citation>
</ref>
<ref id="B51">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grinspoon]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bakalar]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<source><![CDATA[J Psychoactive Drugs]]></source>
<year>1998</year>
<volume>30</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>171-.</page-range></nlm-citation>
</ref>
<ref id="B52">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cannabis substitution. An adjunctive therapeutic tool in the treatment of alcoholism.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mikuriya]]></surname>
<given-names><![CDATA[TH.]]></given-names>
</name>
</person-group>
<source><![CDATA[Med Times]]></source>
<year>1970</year>
<volume>98</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>187-91</page-range></nlm-citation>
</ref>
<ref id="B53">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aggarwal]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Carter]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[ZumBrunnen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Morrill]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mayer]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<source><![CDATA[J Opioid Manag]]></source>
<year>2009</year>
<volume>5</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>153-68</page-range></nlm-citation>
</ref>
<ref id="B54">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Craig]]></surname>
<given-names><![CDATA[WM]]></given-names>
</name>
</person-group>
<source><![CDATA[Efficacy of marijuana in treating chronic non cancer pain. A short review.]]></source>
<year>2006</year>
<publisher-name><![CDATA[Clinical Services, Worker and Employer Services]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B55">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zajicek]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sanders]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Vickery]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nunn]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet]]></source>
<year>2003</year>
<volume>362</volume>
<numero>9395</numero>
<issue>9395</issue>
<page-range>1517-26</page-range></nlm-citation>
</ref>
<ref id="B56">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abrams]]></surname>
<given-names><![CDATA[DI]]></given-names>
</name>
<name>
<surname><![CDATA[Jay]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Shade]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Vizoso]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Reda]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Press]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurology]]></source>
<year>2007</year>
<volume>68</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>515-21</page-range></nlm-citation>
</ref>
<ref id="B57">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Randomized double blind comparison of delta-9-tetrahydroicannabinol (THC) and marijuana as chemotherapy antiemetics]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levitt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Faiman]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hawks]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Proc Am Soc Clin Oncol]]></source>
<year>1984</year>
<volume>3</volume>
<numero>91</numero>
<issue>91</issue>
</nlm-citation>
</ref>
<ref id="B58">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bennett]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Growing pains for metabolomics]]></source>
<year>2005</year>
</nlm-citation>
</ref>
<ref id="B59">
<nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Final draft: Good Manufacture Practices: update supplementary guidelines for the manufacture]]></source>
<year>2005</year>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B60">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[La Fitoterapia como herramienta terapéutica]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cañigueral]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Vila]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Ginecol Obstet Clínica]]></source>
<year>2005</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>43-51</page-range></nlm-citation>
</ref>
<ref id="B61">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Situación actual del sector de las plantas medicinales en España]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blanché]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Espec En Anestesiol Reanim]]></source>
<year>2005</year>
<volume>52</volume>
<page-range>451-2</page-range></nlm-citation>
</ref>
<ref id="B62">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Medical Marijuana and the Law]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoffmann]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2010</year>
<volume>362</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1453-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
